HONG KONG – Carsgen, a Chinese developer of cancer therapies, announced its completion of an undisclosed series A financing led by China-based health care private equity fund BVCF Management Ltd. The proceeds will be used to initiate the clinical trials of Carsgen's lead therapeutic asset.